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1. Introduction
Zika virus is an arbovirus that was discovered many decades ago but remains 
 fundamentally silent until a couple of decades ago. Nevertheless, only when arrived in 
the Americas, was able to cause significant epidemics and new clinical consequences, 
including microcephaly and the Guillain-Barré syndrome, among others. In this 
chapter, we introduce general concepts and our position regard the relevance of Zika 
and their knowledge and experience in the Americas over the last years, 2015–2020.
2. Fundamental aspects of Zika virus and Zika disease
The Zika virus (ZIKV) was first isolated in Uganda in 1947 and was confined 
for almost 60 years in Africa and Asia. Later, in 2007, the Yap outbreak allowed 
its spread to French Polynesia and other Pacific islands in 2013–2015, finally 
reaching the Americas in 2015 and being declared a Public Health Emergency of 
International Importance in 2016. Currently, no area is reporting Zika outbreaks; 
however, its circulation through sporadic cases remains a global threat. The dis-
covery of ZIKV and many other arboviruses was the result of research conducted 
within the Rockefeller Foundation-sponsored yellow fever research programs [1]. 
The current East African Virus Research Institute (Entebbe, Uganda), was a focal 
point for research on pathogenic viruses. In April 1947, in an attempt to map the 
spread of yellow fever, the temperature of Rhesus monkeys, of the Asian species 
(Macaca mulatta), used in six sentinel platforms in the Zika forest in Entebbe, 
Uganda, was measured periodically [2]. On April 18, 1947, the temperature of one 
of these monkeys, Rhesus 766, was reported to be 39.7°C and the next day 40°C, 
so it was taken to the Entebbe laboratory where it was kept under observation for 
30 days, with no evidence of other symptoms. On the third day of fever, a blood 
sample was taken that would subsequently allow the isolation of what was called 
ZIKV (strain 766). In the same report, the first isolation of ZIKV is described in 86 
Aedes africanus mosquitoes trapped on a tree platform in the Zika forest in January 
1948 [2]. Interestingly, although there was no evidence that ZIKV caused disease 
among Ugandan residents, the prevalence of antibodies to ZIKV was 9.5–20%, 
suggesting that the virus was already circulating in the human population (or was 
a consequence of cross-reactivity with other flaviviruses) [3]. A more detailed 
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description of the origins of ZIKV is presented elsewhere [4]. Although the initial 
isolation and characterisation of ZIKV in Uganda’s Zika forest are unquestionable, 
there is some controversy as to which report described the first human ZIKV infec-
tion [5]. Several authors suggest that the first isolation in humans was in 1954, and 
it was a 10-year-old African girl with fever and headache associated with a malaria 
co-infection [6]. Cross-neutralisation tests with convalescent sera from monkeys 
infected with different viruses indicated that only ZIKV-infected serum neutralised 
the virus from the patient’s serum, strongly suggesting ZIKV infection. However, 
a later published report indicated that the virus isolated in West Africa was more 
closely related to the Sponweni virus, and not to the Zika virus [7]. Ten years 
later, in 1964, a report is published of a worker at the East African Virus Research 
Institute in Entebbe who became infected with ZIKV while working on a series of 
new ZIKV strains, and his clinical presentation was characterised headache, diffuse 
pink maculopapular rash, myalgia, fever, and general malaise [8]. Interestingly, the 
author of the report is the same infected patient.
Outside of Africa, ZIKV was first isolated in 1969, in one of 58 groups of 1,277 
Aedes aegypti mosquitoes collected from cities and towns on the Malay Peninsula 
(now Malaysia, Asia) [9]. Then, in 1977 in Indonesia (Asia), human infections of 
ZIKV infection were described, which were clinically characterised by high fever, 
malaise, stomach pain, dizziness and anorexia [10]. Notably, apart from direct 
evidence on ZIKV circulation from previously described human isolates and cases 
of infection, serological studies conducted in the 1950s suggest that ZIKV had a 
widespread distribution in both Africa (East, Central, West and South) as in several 
Asian countries [11]. However, the interpretation of serological results should be 
made with caution because the cross-reactions were not well characterised at that 
time [12]. From the first report of ZIKV infection in humans in 1954 (or 1964) 
through the early 2000s, only a few isolated cases of ZIKV infection disease have 
been documented. However, the outbreak in Yap State “initiates” the events that 
would make ZIKV a potential pandemic threat and are briefly described in Figure 1. 
Other publications describe these milestones in more detail [13–26].
The ZIKV is a member of the Flaviviridae family of viruses, which includes 
small viruses with a positive single-stranded RNA genome (9000–13000 bases) and 
which in turn is composed of 4 genera (Flavivirus, Hepacivirus [hepatitis C virus], 
Pegivirus and Pestivirus) [27]. Although transmission through mosquito bites is the 
Figure 1. 
Chronology of ZIKV infection and reported cases. *ZIKV = Zika virus; GBS = Guillain-Barré syndrome; 
M-F = Maternal-fetal; PHEIC = Public Health Emergency of International Concern.
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primary mechanism for the spread of ZIKV, other routes of transmission have been 
proposed that contribute to the epidemic.
Vector transmission: Transmission through the bite of infected mosquitoes is 
the primary mechanism for the spread of ZIKV. The Aedes aegypti mosquito is the 
primary vector for urban transmission of ZIKV throughout the world. At the same 
time, other Aedes species can act as vectors for ZIKV in specific environments 
where its abundance is essential (e.g. A. albopictus that lives in temperate regions) 
[29]. Aedes mosquitoes can also transmit dengue and chikungunya viruses.
Non-vector transmission: Non-vector transmission events have been reported 
including maternal-fetal transmission, sexual transmission, transmission associ-
ated with transfusion of blood products or organ transplantation, and laboratory 
exposure [30, 31].
3. Clinical features
Possibly the first clinical description of a patient with ZIKV was reported in 1956 
[32]. It was a 34-year-old European volunteer who was inoculated subcutaneously with 
a strain of ZIKV from Nigeria. After an incubation period of 82 hours, he developed a 
frontal headache associated with mild and short-term fever. On the afternoon of the 
fifth day, the headache, fever, and malaise increased in severity. It was accompanied 
by nausea and vertigo (which was attributed to a histamine reaction that responded to 
a small dose of aspirin). By the seventh day, the patient had fully recovered [32]. The 
percentage of asymptomatic ZIKV infections is estimated to be 50–80% [16, 33]. Data 
obtained from the Yap Island seroprevalence study showed that only 19% of those 
infected had symptoms attributable to ZIKV [34]. However, the retrospective serop-
revalence study in French Polynesia showed that, among ZIKV seropositive patients, 
the percentage of symptomatic infections was 47% in adults [35]. That suggests that 
the virus strain could influence the proportion of symptomatic ZIKV infections.
For symptomatic infections, the incubation period varies from 3 to 14 days [36], 
and in most cases, the disease is self-limited [37]. It generally manifests as an itchy 
rash, mild fever, fatigue, myalgia/arthralgia, conjunctivitis, and headache, with an 
average duration of 1 week [37, 38]. The clinical characteristics appear to be similar 
in all age groups, regardless of sex and gestational status. Serious illness requiring 
hospitalisation is rare [9–48]. As observed, especially in some countries of Latin 
America, comorbidities would complicated cases [21–48].
The frequency of complications related to ZIKV infection appears to be low, 
but when they do occur, they are severe and can be fatal [39]. The most commonly 
reported complications to include complications associated with ZIKV infection  
during pregnancy such as congenital ZIKV syndrome (CZS), microcephaly, congeni-
tal malformations or abnormalities, brain abnormalities (e.g., delayed brain growth), 
eye disorders, pregnancy, fetal or perinatal death, hearing disorders, cardiovascular 
damage, neurological complications, intrauterine growth restriction, amniotic fluid 
abnormalities and epilepsy; neurological complications in adults, such as Guillain-
Barré syndrome (https://www.who.int/csr/disease/zika/case-definition/en/); and 
finally death associated with ZIKV infection [40–49].
4. Diagnosis
Because the clinical manifestations of acute ZIKV infection are nonspecific, the 
definitive diagnosis is made by molecular and serological methods [43]. However, 
clinical and epidemiological criteria justify screening tests.
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4.1 Clinical
For ZIKV disease, the clinical criteria for the definition of a suspected case 
according to the Centers for Disease Control and Prevention (CDC, 2016) cor-
responds to a person with one or more of the following (not explained by another 
aetiology) [15–44]:
Suspected case:
• Clinically compatible disease including acute onset of fever (measured or 
reported), maculopapular rash, arthralgia or conjunctivitis; or
• Guillain-Barré syndrome or other neurological manifestations; or
• Complications of pregnancy (e.g., loss of a fetus, fetus or newborn with 
congenital microcephaly, congenital intracranial calcifications, structural 
abnormalities of the brain or eyes, or structural abnormalities related to the 
central nervous system).
Epidemiological link criteria:
• Recent residence or travel to areas with known ZIKV transmission, sexual 
contact with a confirmed or probable case within the transmission risk window 
(2 weeks).
• Receipt of blood, blood products or organ or tissue transplantation within 
30 days after the onset of symptoms.
• Association in time and place with a confirmed or probable case; and
• Probable vector exposure in an area with suitable ecological and seasonal 
conditions for possible local vector transmission.
*An online resource is available through the CDC website (https://wwwnc.cdc.
gov/travel/page/zika-information) to recognise areas with reported cases of ZIKV 
infection.
4.2 Laboratory
The diagnostic approach to ZIKV infection may vary depending on the resources 
available. For patients with suspected ZIKV disease, molecular detection of ZIKV 
RNA (e.g. nucleic acid amplification tests or NAAT [by RT-PCR]) is the preferred 
diagnostic method because they can provide confirmed evidence of infection and 
distinguish the specific virus [45, 46]. However, nucleic acid tests only show the 
presence of ZIKV RNA but do not necessarily indicate the presence of infectious 
viruses. On the other hand, serological tests (e.g. IgM antibodies [employing an 
immunosorbent assay linked to IgM antibody capture enzymes or MAC-ELISA]) or 
IgG [by plaque reduction neutralisation test or PRNT] against ZIKV are They are 
used mainly in patients who present after the viral nucleic acid is no longer detect-
able [20–48], despite the number of false-positive results due to cross-reactivity 
with other flaviviruses.
The algorithm for recommendations and the interpretation of the results of the 
dengue virus and ZIKV diagnostic tests are described in Figure 2.
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4.2.1 Pregnant women
Pregnant women with a clinically compatible disease and possible exposure to 
ZIKV or dengue virus should be evaluated as soon as possible (Figure 3). Evaluation 
for ZIKV and dengue infection is performed by performing NAAT and IgM antibody 
testing on serum sample and NAAT on a urine sample. NAATs can be performed on 
Figure 2. 
Algorithm of recommendations for testing ZIKV and dengue virus for people with the clinically compatible disease 
and risk for infection with both viruses. *And risk for infection with both viruses. Adapted and modified from CDC.
Figure 3. 
Algorithm of recommendations for testing ZIKV and dengue virus for pregnant women with the clinically 
compatible disease and risk for infection with both viruses. *And risk for infection with both viruses. Adapted 
and modified from CDC.
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plasma, cerebrospinal fluid whole blood, or amniotic fluid; likewise, IgM antibody 
tests can be performed on plasma, whole blood, or cerebrospinal fluid. Specimens 
should be collected as soon as possible and within 12 weeks of the onset of symp-
toms. A positive NAAT result in any sample provides sufficient evidence of a recent 
infection. However, suppose the NAAT is only positive for ZIKV in a single sample, 
and the IgM antibody test is negative. In that case, the NAAT should be repeated with 
fresh RNA from the same sample to rule out false-positive results. If the NAAT is 
negative, but the IgM antibody test is positive, confirmatory PRNTs should be per-
formed for dengue, ZIKV, and other flaviviruses endemic to the region (Figure 3).
For asymptomatic pregnant women without continued risk of possible Zika 
virus infection, routine screening for ZIKV infection is not recommended. 
However, the assessment must be considered in terms of risk and through a shared 
decision-making model. A more detailed review is described elsewhere [15–39].
The algorithm of recommendations and the interpretation of the results of the 
dengue virus and ZIKV diagnostic tests in pregnant women are described in Figure 2.
5. Classification of cases
The definition of suspected cases was previously described. According to the 
CDC [44], suspected cases should be classified into:
6. Differential diagnostics
Differential diagnosis includes Dengue fever, Chikungunya virus, West Nile 
virus, Yellow fever, Malaria infection, Leptospirosis, Rubella, infectious Erythema 
(parvovirus B19 infection), Rocky Mountain spotted fever, Group A streptococcal 
infection, alphavirus infections, and coronavirus disease 2019 (COVID-19) [15–41]. 
Also, Mayaro, and the proposed ChikDenMaZika syndrome should be considered 
in the differential diagnostics [15–41].
7. Treatment of ZIKV disease
There is no specific treatment for ZIKV infection [15–43], and current treat-
ment recommendations are based on limited evidence [15–44]. Thus, as with other 
Probable case Confirmed case
• Clinical criteria for ZIKV disease; and
• Epidemiological link; and
• Laboratory evidence of recent ZIKV or 
flavivirus infection by:
 ○ Positive test of IgM antibodies against 
ZIKV in serum or CSF; and
 ○ Positive neutralising antibody titers (e.g. 
PRNT) against ZIKV, dengue or other 
flaviviruses endemic to the region where 
the exposure occurred; or
 ○ Negative test for IgM antibodies against 
dengue virus, and no neutralising antibody 
tests were performed.
• Clinical criteria for ZIKV disease; and
• Laboratory evidence of recent ZIKV infection by:
 ○ Detection of ZIKV by culture, viral antigen 
or viral RNA in serum, CSF, tissue or another 
sample (e.g. amniotic fluid, urine, semen, 
saliva); or
 ○ Positive serum or CSF IgM antibody test against 
ZIKV with positive ZIKV neutralising antibody 
titers (≥10) and negative neutralising antibody 
titers against dengue or other endemic flavivi-
ruses in the region of exposure.
* The criteria for WHO/PAHO are similar (www.paho.org).
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mosquito-borne flaviviruses, treatment for ZIKV infection is symptomatic and 
supportive and includes [15–45]:
7.1 Symptomatic and supportive treatment
• Rest and adequate hydration.
• Use of analgesics or antipyretics: Acetaminophen 325–1000 mg orally every 
4 to 6 hours when necessary (maximum 4000 mg/day). Aspirin and other 
non-steroidal anti-inflammatory drugs (NSAIDs) should be avoided until 
dengue virus infection has been ruled out, to reduce the risk of  
bleeding.
• Calamine lotion can be used for the maculopapular rash.
* The management of pregnant women, congenital Zika syndrome, and Guillain-
Barré syndrome is described in detail elsewhere [15–41].
Although a large number of existing drugs and novel chemical compounds 
have been postulated as possible interventions against ZIKV [15–46] and some 
have shown activity against ZIKV in animal and experimental models [15–48], 
none have yet demonstrated safety and efficacy in clinical trials [15-49]. A 
safety and tolerability trial for the monoclonal antibody against ZIKV called 
Tyzivumab (NCT03443830), and another for a polyclonal antibody against ZIKV 
(NCT03624946) have completed their recruitment phase and are currently in prog-
ress. At the moment, there are no treatments approved by government agencies for 
ZIKV, and there is no information to suggest that there are treatments in advanced 
stages of development [20–40].
8. Advances in vaccination
Significant efforts have been made to develop safe and effective vaccines against 
ZIKV. International scientific cooperation has resulted in multiple candidate vac-
cines that are now in various stages of clinical and preclinical development [22–42]. 
Several vaccines are being developed, including purified inactivated viral particles 
(PIV), purified virus-like particles (VLPs) and viral subunit proteins, live attenu-
ated vaccines, chimeric vaccines, and viral and non-viral vectors that encode ZIKV 
structural proteins [20–43]. The most advanced candidate corresponds to a DNA 
vaccine (VRC5283) developed by the National Institute of Allergy and Infectious 
Diseases (NIAID) that is being evaluated in phase 2 clinical study (NCT03110770) 
that seeks to evaluate the safety and tolerability of the vaccine. (Phase A) and the 
safety and efficacy compared to placebo (Phase B); that is, the safety, immunoge-
nicity, optimal dose of administration are evaluated, and an attempt will be made to 
determine the ability of the vaccine to prevent the disease caused by ZIKV infection 
effectively. At the time of this writing, the results published on www.clinical.trials.
gov had not completed the quality control review process. However, its results have 
been promising [20–44]. However, significant challenges remain in the develop-
ment of vaccines for ZIKV. Difficulties include the heterogeneity of the incidence of 
ZIKV infection, difficulties in financing, regulation and authorisation of vaccines, 
which in turn has limited the conduct of phase 2 and 3 clinical trials and prompted 
international organisations to consider approaches alternative, as models of infec-
tion by controlled human exposure [25–46]. Vaccine development for ZIKV is 
underway.
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9. Conclusions
The impact and burden of Zika in the Americas region have multiple implica-
tions. Clinical and epidemiological research has been vital in the understanding 
and developing of knowledge for the management and prevention of this emerging 
arboviral disease [30–48]. Still, many challenges exist, including the developing of 
an effective vaccine, still under developing.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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